文献速递炎症性肠病

瑞典全国性研究:新发与现患克罗恩病和溃疡性结肠炎的医疗使用、工作损失与总费用

Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.
PubMed 文献 · Aliment Pharmacol Ther · 2020-07-03

基于瑞典患者登记册纳入现患克罗恩病10117例、溃疡性结肠炎19762例及新发病例4028例和8659例,每例匹配5名人群对照,估算 societal 成本。现患克罗恩病和溃疡性结肠炎患者年均 societal 成本分别为22813美元和14136美元,高于对照的7533美元和7351美元;新发患者首年总成本超过对照三倍。

要点

  • 工作年龄克罗恩病患者年均 societal 成本22813美元,溃疡性结肠炎14136美元,均高于对照。
  • 克罗恩病和溃疡性结肠炎成本主要来自生产力损失,分别占56%和59%。
  • 克罗恩病抗TNF使用率22.2%高于溃疡性结肠炎7.4%,年残疾养老金44天对25天。

核心结论

  • 在瑞典,新发和现患克罗恩病与溃疡性结肠炎患者的 societal 成本 consistently 为一般人群的2至3倍。

研究设计与样本

  • 基于瑞典患者登记册的全国性研究,纳入2014年1月1日年龄≥18岁的现患克罗恩病10117例和溃疡性结肠炎19762例,以及2010-2013年新发成人克罗恩病4028例和溃疡性结肠炎8659例,每例匹配5名人群对照。

主要发现

  • 工作年龄(18-64岁)克罗恩病患者年均 societal 成本22813美元,对照7533美元;溃疡性结肠炎患者14136美元,对照7351美元。
  • 年龄≥65岁克罗恩病患者年均成本9726美元,对照3875美元;溃疡性结肠炎患者8072美元,对照4016美元。
  • 克罗恩病患者成本56%来自生产力损失,溃疡性结肠炎患者59%来自生产力损失。
  • 工作年龄克罗恩病患者抗TNF使用率22.2%,溃疡性结肠炎7.4%;年残疾养老金分别为44天和25天。
  • 新发克罗恩病和溃疡性结肠炎患者首年人均总成本超过对照三倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC). AIM: To estimate the societal cost of actively treated CD and UC in Sweden. METHODS: We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave. RESULTS: The mean annual societal costs per working-age patient (18-64 years) with CD and UC were $22 813 (vs $7533 per comparator) and $14 136 (vs $7351 per comparator), respectively. In patients aged ≥65 years, the mean annual costs of CD and UC were $9726 and $8072 vs $3875 and $4016 per comparator, respectively. The majority of cost for both CD (56%) and UC (59%) patients originated from productivity losses. Higher societal cost of working-age CD patients as compared to UC patients was related to greater utilisation of anti-TNF (22.2% vs 7.4%) and increased annual disability pension (44 days vs 25 days). Among incident CD and UC patients, the mean total cost over the first year per patient was over three times higher than comparators. CONCLUSION: In Sweden, the societal cost of incident and prevalent CD and UC patients was consistently two to three times higher than the general population.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Khalili H, Everhov ÅH, Halfvarson J, et al. Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther. 2020. PMID: 32902894. doi:10.1111/apt.15889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。